Inovactis SAS is a synthetic biology startup located at G_nopole dEvry, is developing modified yeasts with neoantigenes which is capable of triggering immune response against skin cancer.
Inovactis collaborates with the Curie Institute (Paris V) for its cancer in vivo trials.
Inovactis has a partnership with Traaser, a genomic data company located at Genopole, for the patient neoantigens discovery.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/inovactis” connections=”true” suffix=””]
Inovactis yeast platform technology developes a genetically modified S. cerevisiae (yeast) immunotherapy to safely induce a targeted immune response against any cancer type by. Inovactis engineers the yeast to produce specific tumor neoantigens and antibodies that modify in vivo the patient immune system by targeting dendritic cells directly in vivo, without any cell extraction from the patient.
In Jan 2017, Inovactis received from Paris-Saclay University, grant of 16,700 Euros to explore the feasibility of the project.